ArticleScientific reports2022
Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn's disease.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Next Generation Probiotics Challenges: A Road to use as Live Bio-Therapeutics.Current microbiology · 2026Review
- Christensenella minuta DSM 22607 and Food Restriction Manage Age-Related Disorders In Vivo.Probiotics and antimicrobial proteins · 2026Article
- Does Intrarectal Administration ofNutrients · 2026Article
- Amelioration of colitis through restored gut ecology using Christensenella intestinihominis AF73-05CM02 as a probiotic in mice.Communications biology · 2026Article
- Membrane vesicles produced by next-generation probiotics from the gut as innovative tools for human health.Gut microbes · 2025Review
- Potential and Challenges ofFoods (Basel, Switzerland) · 2025Review
- Dual effects of probiotic administration prior to Mycobacterium avium subsp. paratuberculosis infection are associated with immunological and microbiota shifts.Scientific reports · 2025Article
- Clinical translation of microbiome research.Nature medicine · 2025Review
- Achieving healthy aging through gut microbiota-directed dietary intervention: Focusing on microbial biomarkers and host mechanisms.Journal of advanced research · 2025Review
- Development of Next Generation Probiotics for Cardiometabolic Diseases.Phenomics (Cham, Switzerland) · 2025Article
- Deleterious Effects of Yoyo Dieting and Resistant Starch on Gastrointestinal Morphology.Nutrients · 2024Article
- Characteristics of the Gut Microbiota Composition of the Arctic Zone Residents in the Far Eastern Region.Biomedicines · 2024Article
- Review
- The Plethora of Microbes with Anti-Inflammatory Activities.International journal of molecular sciences · 2024Review
- Probiotic-Induced Modulation of Microbiota Composition and Antibiotic Resistance Genes Load, an In Vitro Assessment.International journal of molecular sciences · 2024Article
- Article
- A flexible high-throughput cultivation protocol to assess the response of individuals' gut microbiota to diet-, drug-, and host-related factors.ISME communications · 2024Article
- A Keystone Gut BacteriumFoods (Basel, Switzerland) · 2023Review
- Alteration of gut microbiota in wild-borne long-tailed macaques after 1-year being housed in hygienic captivity.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbiome-based therapies for inflammatory bowel diseases offer a novel and promising therapeutic approach. The human commensal bacteria of the species Christensenella minuta (C. minuta) have been reported consistently missing in patients affected by Crohn's disease (CD) and have been documented to induce anti-inflammatory effects in human epithelial cells, supporting their potential as a novel biotherapy. This work aimed at selecting the most promising strain of C. minuta for future development as a clinical candidate for CD therapy. Here, we describe a complete screening process combining in vitro and in vivo assays to conduct a rational selection of a live strain of C. minuta with strong immunomodulatory properties. Starting from a collection of 32 strains, a panel of in vitro screening assays was used to narrow it down to five preclinical candidates that were further screened in vivo in an acute TNBS-induced rat colitis model. The most promising candidate was validated in vivo in two mouse models of colitis. The validated clinical candidate strain, C. minuta DSM 33715, was then fully characterized. Hence, applying a rationally designed screening algorithm, a novel strain of C. minuta was successfully identified as the most promising clinical candidate for CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.